Alzheimer's Disease | Special Topics | Detailed, Expanded Analysis - Special Topics (US & EU)

Publish date: June 2019

Login to access report

Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to include a growing pool of novel strategies that target tau, the other pathological hallmark of AD. Though most tau-targeted therapies are in early-phase (I or II) development, many of them are sponsored by large pharma with a strong neurology/AD presence (e.g., AbbVie, Janssen, Merck, Biogen). Dissecting the ongoing clinical development programs—mechanism of action (stabilization, aggregation, and/or phosphorylation of tau), supportive evidence/clinical data, trial design, etc.—will help current pioneers and new players in this space understand the evolving competitive landscape. Simultaneously, because biomarkers will play an increasingly important role in the screening of patients and clinical assessment of DMTs, it is critical to understand ongoing developments in this arena and neurologists’ perspectives on the future of biomarkers in AD.

Questions Answered

  • What is the landscape for emerging tau-targeted therapies and biomarkers in AD? What are the key features in the ongoing clinical trials?
  • What are interviewed KOLs’ opinions about new tau-targeted therapies in development, and the role of tau vs. amyloid in the pathology of AD?
  • How do experts in the field believe these agents compare with the late-phase anti-Aβ therapies?
  • How is the role of molecular biomarkers in AD research evolving?

Product Description

DRG’s Special Topics reports assess key trends in dynamic disease areas. This report on AD will help developers gain needed insight into the rapidly growing area of tau and biomarker research in AD that could shape the future of this market.

Geographies: United States

Primary research: Interviews with 15 neurologists/tau thought leaders across the United States and Europe

Key drugs covered: Clinical-stage tau compounds, including LMTX, AADvac1, ABBV-8E12, LY3303560, gosuranemab, BIIB-076, BIIB-080.

Key insights provided:

  • Pipeline review: anti-tau therapies and biomarkers in AD.
  • KOLs’ awareness and perceptions of key anti-tau therapies.
  • KOLs’ opinions of discrete tau targets.
  • Expectations from tau-targeted therapies vs. other disease-modifying approaches.
  • KOLs’ insight on biomarkers.

Table of contents

  • Detailed, Expanded Analysis - Special Topics (US & EU)
    • Anti-Tau Therapies and Biomarkers in Alzheimer's Disease

Author(s): Ruchita Kumar, Ph.D

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.